CAS 331731-18-1: ImmunoglobulinG1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain),disulfide with human monoclonal D2E7 light chain, dimer

Description: Immunoglobulin G1 (IgG1), specifically the anti-human tumor necrosis factor (TNF) monoclonal antibody D2E7, is a therapeutic protein designed to inhibit TNF, a cytokine involved in systemic inflammation. This dimeric structure consists of two heavy chains and two light chains linked by disulfide bonds, which stabilize the antibody's conformation and enhance its functionality. IgG1 is characterized by its ability to bind specifically to TNF, thereby neutralizing its activity and reducing inflammation associated with autoimmune diseases such as rheumatoid arthritis. The molecular structure of D2E7 allows for high specificity and affinity for TNF, making it effective in clinical applications. Additionally, the presence of disulfide bonds contributes to the stability and longevity of the antibody in circulation. As a therapeutic agent, it is administered via injection and has been shown to improve patient outcomes by alleviating symptoms and slowing disease progression. Overall, D2E7 exemplifies the use of monoclonal antibodies in targeted therapy for inflammatory conditions.

Synonyms:

• Adalimumab
• D 2E7
• Humira
• Unii-fys6T7F842

Adalimumab

CAS: 331731-18-1

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human …

• Purity: 95% - 99.50%
• Color and Shape: Liquid
• Molecular weight: 145.4 kDa

Adalimumab

CAS: 331731-18-1

Monoclonal antibody against TNF-α; therapy for rheumatoid arthritis

• Formula: C₆₄₂₈H₉₉₁₂N₁₆₉₄O₁₉₈₇S₄₆
• Purity: Min. 95%
• Color and Shape: Clear Liquid
• Molecular weight: 144099.37971